RxDoctor Payments Data

Nadia Blanchet, MD

Plastic and Reconstructive Surgery · Richmond, VANPI 1851402515

Payments from drug & device makers

What this record shows

The money is spread across several categories — gifts (50.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by AbbVie at 53.9% of the total. Reporting peaked in 2019 at $2,421 and has fallen 97.5% since, to $62 in 2025.

$3,810in general payments, 2019–2025

Across 49 payments — averaging $77.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Musculoskeletal Transplant Foundation Inc.$1K
  • Mentor Worldwide LLC$257
  • Galderma Laboratories, L.p.$132
  • Revance Therapeutics, Inc.$62
  • TELA Bio, Inc.$38
  • plus $125 from 5 others

What the payments were for

  • Food & beverage$1,87149%
  • Education$281%
  • Gifts$1,91150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,810 in reported general payments places this provider in the 55th percentile of 77 plastic and reconstructive surgery providers in Virginia.

See all plastic and reconstructive surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$43,992
Medicare patients
46
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib29$520
Montelukast Sodium40$169
Cefadroxil44$147
Tranexamic Acid28$131
Ondansetron OdtOndansetron22$127
Acyclovir17$38
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$31

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →